135 related articles for article (PubMed ID: 33984892)
1. Determinants of remission in a case series of medullary thyroid carcinoma.
Apaydın T; İmre E; Yavuz D
Turk J Med Sci; 2021 Aug; 51(4):2050-2056. PubMed ID: 33984892
[TBL] [Abstract][Full Text] [Related]
2. An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.
Duval MADS; Ferreira CV; Marmitt L; Dora JM; Espíndola M; Benini AF; Camelier MV; Bulzico D; Andrade FA; Alves Júnior PA; Corbo R; Vaisman F; Zanella AB; Scheffel RS; Maia AL
Thyroid; 2023 Jan; 33(1):82-90. PubMed ID: 36222615
[No Abstract] [Full Text] [Related]
3. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
4. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
[TBL] [Abstract][Full Text] [Related]
5. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.
Franc S; Niccoli-Sire P; Cohen R; Bardet S; Maes B; Murat A; Krivitzky A; Modigliani E;
Clin Endocrinol (Oxf); 2001 Sep; 55(3):403-9. PubMed ID: 11589685
[TBL] [Abstract][Full Text] [Related]
6. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
7. Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan.
Ito Y; Miyauchi A; Kihara M; Higashiiyama T; Fukushima M; Miya A
World J Surg; 2018 Dec; 42(12):3954-3966. PubMed ID: 30051240
[TBL] [Abstract][Full Text] [Related]
8. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
[TBL] [Abstract][Full Text] [Related]
10. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
[No Abstract] [Full Text] [Related]
11. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
12. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Scollo C; Baudin E; Travagli JP; Caillou B; Bellon N; Leboulleux S; Schlumberger M
J Clin Endocrinol Metab; 2003 May; 88(5):2070-5. PubMed ID: 12727956
[TBL] [Abstract][Full Text] [Related]
13. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
Jin LX; Moley JF
Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
[TBL] [Abstract][Full Text] [Related]
14. Can procalcitonin be useful for medullary thyroid cancer?
Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma.
Park H; Park SY; Park J; Choe JH; Chung MK; Woo SY; Choi JY; Kim SW; Chung JH; Kim TH
Front Endocrinol (Lausanne); 2021; 12():749973. PubMed ID: 34675884
[TBL] [Abstract][Full Text] [Related]
17. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
Torresan F; Mian C; Cavedon E; Iacobone M
Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
[TBL] [Abstract][Full Text] [Related]
18. CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA.
Filimon S; Payne RJ; Black MJ; Hier MP; Mlynarek AM; Forest VI; Tamilia M
Endocr Pract; 2018 May; 24(5):460-467. PubMed ID: 29847167
[TBL] [Abstract][Full Text] [Related]
19. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]